Resona Asset Management Co. Ltd. Trims Stock Holdings in DaVita Inc. $DVA

Resona Asset Management Co. Ltd. decreased its position in DaVita Inc. (NYSE:DVA) by 96.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 449 shares of the company’s stock after selling 13,686 shares during the period. Resona Asset Management Co. Ltd.’s holdings in DaVita were worth $51,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Elevation Wealth Partners LLC raised its stake in DaVita by 147.3% in the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in DaVita in the 2nd quarter worth $43,000. iSAM Funds UK Ltd purchased a new position in DaVita in the 3rd quarter worth $46,000. Stance Capital LLC purchased a new position in DaVita in the 3rd quarter worth $47,000. Finally, Camelot Portfolios LLC purchased a new position in DaVita in the 4th quarter worth $57,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Activity at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

DaVita Stock Performance

NYSE DVA opened at $198.39 on Monday. The stock has a 50-day simple moving average of $162.93 and a two-hundred day simple moving average of $138.27. The firm has a market capitalization of $12.74 billion, a P/E ratio of 18.40, a PEG ratio of 0.65 and a beta of 0.84. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $202.69.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the business posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts forecast that DaVita Inc. will post 15.07 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. UBS Group raised their target price on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Barclays lifted their price objective on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, TD Cowen lifted their price objective on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and an average target price of $199.17.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.